



A product of AmeriHealth Caritas North Carolina, Inc.

July 25, 2025

Humira Biosimilars Updates

Dear Provider,

Over the past few years, the FDA has approved a number of biosimilars for Humira (adalimumab). All biosimilars are FDA approved for the same indications as branded Humira. Humira will be removed from the AmeriHealth Caritas Next formularies as of **9/1/2025**. The following Humira biosimilar medications will be available on the formulary at Tier 4 and require a prior authorization:

Proprietary Name	Non-proprietary name	Interchangeability with Humira
Abrilada	(adalimumab-afzb)	Υ
adalimumab-aaty	(adalimumab-aaty)	Υ
adalimumab-fkjp	(adalimumab-fkjp)	Υ
Hadlima	(adalimumab-bwwd)	Υ
Simlandi	(adalimumab-ryvk)	Υ
Yusimry	(adalimumab-aqvh)	N

All biosimilars except Yusimry are interchangeable with Humira. Interchangeable biosimilars do not require a new prescription.

Please assess and if clinically appropriate, consider the use of one of the above biosimilars in place of branded Humira for your patients in the future. If you have any questions, please reach out to Perform Rx General Assistance at **1-844-211-0968**.

Thank you,

Pharmacy Services
AmeriHealth Caritas Next

AmeriHealth Caritas Next and First Choice Next are individual and family health plans offered both on and off the Health Insurance Marketplace® by certain companies within the AmeriHealth Caritas Family of Companies. AmeriHealth Caritas Next is offered by AmeriHealth Caritas VIP Next, Inc. in Delaware; AmeriHealth Caritas Florida, Inc. in Florida; AmeriHealth Caritas North Carolina, Inc. in North Carolina; and First Choice Next by Select Health of South Carolina, Inc. in South Carolina.